Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2023

Seagen - HER2-Targeted Therapies in mCRC: Are We Ready for a Paradigm Shift?

Exploring New Opportunities to Improve Outcomes in Patients with HER2+ mCRC

Date

20 Oct 2023

Session

Seagen - HER2-Targeted Therapies in mCRC: Are We Ready for a Paradigm Shift?

Topics

Targeted Therapy

Tumour Site

Colon and Rectal Cancer

Presenters

Salvatore Siena

Authors

S. Siena

Author affiliations

  • Hemato-oncology Dept., UNIMI - Università degli Studi di Milano Statale, 20121 - Milan/IT

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Welcome and Introduction

Presenter: Salvatore Siena

Session: Seagen - HER2-Targeted Therapies in mCRC: Are We Ready for a Paradigm Shift?

Resources:

Webcast

The Role of HER2 Testing in mCRC

Presenter: Richard Adams

Session: Seagen - HER2-Targeted Therapies in mCRC: Are We Ready for a Paradigm Shift?

Resources:

Webcast

Closing Remarks

Presenter: Salvatore Siena

Session: Seagen - HER2-Targeted Therapies in mCRC: Are We Ready for a Paradigm Shift?

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.